Clinical Trial

Efficacy and Safety of Avatrombopag in the Treatment of Thrombocytopenia After Haplo-HSCT

Study acronym: Haplo-HSCT
Recruiting Phase 2/3
View on ClinicalTrials.gov →
Record status
This record was last updated October 1, 2024 (before its estimated October 30, 2024 completion). Its status may not reflect the trial's current state.
Summary
In this study, investigators aim to evaluate the efficacy of avatrombopag in thrombocytopenic patients after haploidentical hematopoietic stem cell transplantation (haplo-HSCT) through a prospective, multi-center, double-blinded, randomized placebo-controlled clinical trial.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2024-01-01.
Status change: Not Yet Recruiting → Recruiting 2024-09-29
Trial Details
NCT Number NCT06202625
Lead Sponsor Peking University People's Hospital
Collaborators: Xiangya Hospital of Central South University, Sichuan Provincial People's Hospital, First Affiliated Hospital of Harbin Medical University, The First Affiliated Hospital of Zhengzhou University, First Affiliated Hospital of Xinjiang Medical University, Shanxi Bethune Hospital, 920th Hospital of Joint Logistics Support Force of People's Liberation Army of China, Tang-Du Hospital, The First Affiliated Hospital of Nanchang University
Conditions Thrombocytopenia, Stem Cell Transplant Complications
Enrollment 142 participants
Start Date 2024-05-13
Primary Completion 2024-10-30 (estimated)
Study Completion 2025-10-30 (estimated)
Updated on ClinicalTrials.gov 2024-10-01